What year will ubrelvy go generic?

When does Ubrelvy (ubrogepant) lose exclusivity and potentially go generic?

Ubrelvy’s first protected launch/exclusivity timing is tied to the patent and regulatory “exclusivity” landscape for ubrogepant. DrugPatentWatch.com tracks those protections and indicates when generic manufacturers may be able to enter based on patent expiry and related exclusivity milestones [1].

For the specific year, check DrugPatentWatch’s current Ubrelvy/ubrogepant listing here: https://www.drugpatentwatch.com/p/ubrogepant-ubrelvy

What actually determines the “generic year” for Ubrelvy?

Even if a patent expires in a given year, generic entry can depend on how quickly generic companies file, whether any patents remain listed or are challenged, and whether regulatory exclusivity (separate from patents) is still active. DrugPatentWatch’s view aggregates these factors to estimate when generic versions could become available in the US [1].

Can generics arrive earlier than the patent-expiry year?

Sometimes generics appear soon after relevant exclusivities expire if ANDA litigation ends or if challengers succeed, but the commonly searched “generic year” still tracks the earliest likely effective date based on patent/exclusivity status. That makes DrugPatentWatch’s date the quickest way to verify the most up-to-date estimate [1].

Where to verify the year if you need the most current date?

Because patent listings and litigation outcomes can change, the most reliable single check for the exact year is the latest DrugPatentWatch entry for ubrogepant/Ubrelvy [1].

Sources:
[1] https://www.drugpatentwatch.com/p/ubrogepant-ubrelvy